JP2005535608A - エポシロンを含む組み合わせおよびその薬学的使用 - Google Patents

エポシロンを含む組み合わせおよびその薬学的使用 Download PDF

Info

Publication number
JP2005535608A
JP2005535608A JP2004510831A JP2004510831A JP2005535608A JP 2005535608 A JP2005535608 A JP 2005535608A JP 2004510831 A JP2004510831 A JP 2004510831A JP 2004510831 A JP2004510831 A JP 2004510831A JP 2005535608 A JP2005535608 A JP 2005535608A
Authority
JP
Japan
Prior art keywords
inhibitor
topoisomerase
hydrogen
lower alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004510831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535608A5 (enExample
Inventor
ジョン・アーサー・ホーネカー
ジュリー・アン・ミラー
ジョン・デイビッド・ロサーメル
マルクス・ヴァルトマン
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2005535608A publication Critical patent/JP2005535608A/ja
Publication of JP2005535608A5 publication Critical patent/JP2005535608A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004510831A 2002-06-10 2003-06-06 エポシロンを含む組み合わせおよびその薬学的使用 Pending JP2005535608A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US38702502P 2002-06-10 2002-06-10
US40623802P 2002-08-27 2002-08-27
US40623902P 2002-08-27 2002-08-27
US43867703P 2003-01-08 2003-01-08
US43867603P 2003-01-08 2003-01-08
PCT/EP2003/005988 WO2003103712A1 (en) 2002-06-01 2003-06-06 Combinations comprising epothilones and pharmaceutical uses thereof

Publications (2)

Publication Number Publication Date
JP2005535608A true JP2005535608A (ja) 2005-11-24
JP2005535608A5 JP2005535608A5 (enExample) 2006-07-20

Family

ID=29741146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004510831A Pending JP2005535608A (ja) 2002-06-10 2003-06-06 エポシロンを含む組み合わせおよびその薬学的使用

Country Status (16)

Country Link
US (2) US20050271669A1 (enExample)
EP (2) EP2179745A1 (enExample)
JP (1) JP2005535608A (enExample)
CN (2) CN101816792A (enExample)
AT (1) ATE476995T1 (enExample)
AU (1) AU2003242646A1 (enExample)
BR (1) BR0311714A (enExample)
CA (1) CA2487147A1 (enExample)
DE (1) DE60333754D1 (enExample)
IL (1) IL165180A0 (enExample)
MX (1) MXPA04012444A (enExample)
NO (1) NO20050096L (enExample)
PL (1) PL372070A1 (enExample)
SG (1) SG162616A1 (enExample)
WO (1) WO2003103712A1 (enExample)
ZA (1) ZA200409137B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019537583A (ja) * 2016-10-28 2019-12-26 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストン脱アセチル化酵素阻害剤及びエポチロンを含む医薬品組み合わせならびにその使用方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2615105A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080242648A1 (en) * 2006-11-10 2008-10-02 Syndax Pharmaceuticals, Inc., A California Corporation COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2009015203A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
WO2009015237A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
WO2009126662A1 (en) * 2008-04-08 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
CA2927832C (en) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001507716A (ja) * 1996-12-03 2001-06-12 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
WO2001064650A2 (en) * 2000-03-01 2001-09-07 Sloan-Kettering Institute For Cancer Research Center Synthesis of epothilones, intermediates thereto and analogues thereof
WO2001072721A2 (en) * 2000-03-27 2001-10-04 Bristol-Myers Squibb Company Synergistic methods and compositions for treating cancer
WO2001081341A2 (de) * 2000-04-20 2001-11-01 Schering Aktiengesellschaft 9-oxa-epothilon-derivate, verfahren zu deren herstellung sowie ihre verwendung in pharmazeutischen präparaten
WO2001081342A2 (de) * 2000-04-19 2001-11-01 Schering Aktiengesellschaft Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
JP2002504540A (ja) * 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
WO2002022577A2 (en) * 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
KR20080016756A (ko) * 1998-02-05 2008-02-21 노파르티스 아게 유기화합물 함유 조성물
AU5036999A (en) * 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
EE200100422A (et) * 1999-02-11 2002-12-16 Schering Aktiengesellschaft Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
ATE554756T1 (de) * 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001507716A (ja) * 1996-12-03 2001-06-12 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
JP2002504540A (ja) * 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
WO2001064650A2 (en) * 2000-03-01 2001-09-07 Sloan-Kettering Institute For Cancer Research Center Synthesis of epothilones, intermediates thereto and analogues thereof
WO2001072721A2 (en) * 2000-03-27 2001-10-04 Bristol-Myers Squibb Company Synergistic methods and compositions for treating cancer
WO2001081342A2 (de) * 2000-04-19 2001-11-01 Schering Aktiengesellschaft Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
WO2001081341A2 (de) * 2000-04-20 2001-11-01 Schering Aktiengesellschaft 9-oxa-epothilon-derivate, verfahren zu deren herstellung sowie ihre verwendung in pharmazeutischen präparaten
WO2002022577A2 (en) * 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019537583A (ja) * 2016-10-28 2019-12-26 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストン脱アセチル化酵素阻害剤及びエポチロンを含む医薬品組み合わせならびにその使用方法
JP2022184965A (ja) * 2016-10-28 2022-12-13 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤及びエポチロンを含む医薬品組み合わせならびにその使用方法
US11998546B2 (en) 2016-10-28 2024-06-04 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and epothilone and methods of use thereof
JP7542947B2 (ja) 2016-10-28 2024-09-02 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤及びエポチロンを含む医薬品組み合わせならびにその使用方法

Also Published As

Publication number Publication date
AU2003242646A1 (en) 2003-12-22
EP1515750A1 (en) 2005-03-23
CN101816792A (zh) 2010-09-01
NO20050096L (no) 2005-02-04
CN1658904A (zh) 2005-08-24
ATE476995T1 (de) 2010-08-15
MXPA04012444A (es) 2005-04-19
EP1515750B1 (en) 2010-08-11
US20050271669A1 (en) 2005-12-08
WO2003103712A1 (en) 2003-12-18
CA2487147A1 (en) 2003-12-18
PL372070A1 (en) 2005-07-11
EP2179745A1 (en) 2010-04-28
ZA200409137B (en) 2005-08-31
HK1075208A1 (en) 2005-12-09
DE60333754D1 (de) 2010-09-23
IL165180A0 (en) 2005-12-18
US20110033458A1 (en) 2011-02-10
BR0311714A (pt) 2005-03-01
SG162616A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
US20110033458A1 (en) Combinations comprising epothilones and pharmaceutical uses thereof
JP6904640B2 (ja) 癌の処置
EP4506004A1 (en) Pharmaceutical composition, use thereof, and method for treating cancer
JP2021059564A (ja) 癌治療のための併用療法
JP2023533447A (ja) がんを処置する併用療法
US20040034026A1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
TW200840583A (en) Methods of treatment
TW200533339A (en) Therapeutic synergy of anti-cancer compounds
CN102665711A (zh) 青蒿素基药物与其他化学治疗剂的抗癌组合物
CN1511036B (zh) 包含信号转导抑制剂和埃坡霉素衍生物的联合形式
US20050033034A1 (en) Anti-t cell immunotoxin fusion protein and its therapeutic use
JP2005535608A5 (enExample)
JPH02502546A (ja) 抗ひきつけ剤組成物および方法のためのデキストロルファン相乗的協力剤
KR100954625B1 (ko) 선택적 사이클로옥시게나제-2 억제제를 포함하는 조합물
JP2007520522A (ja) （ａ）ＤＮＡトポイソメラーゼ阻害剤および（ｂ）ＩＡＰ阻害剤の組み合わせ剤
RU2379032C2 (ru) Комбинации, включающие эпотилоны, и их фармацевтическое применение
AU2008200068B2 (en) Combinations comprising epothilones and pharmaceutical uses thereof
NZ537040A (en) Treating a proliferative disease comprising administering to the animal a combination that comprises (a) a HER-1 or a HER-2 antibody or (b) at least one antineoplastic agent
HK1141234A (en) Combinations comprising epothilones and pharmaceutical uses thereof
KR20050019125A (ko) 에포틸론을 포함하는 조합물 및 그의 제약적 용도
EP1485090B1 (en) Combinations comprising an epothilone derivative and an imidazotetrazinone
CN1758908A (zh) 用埃坡霉素衍生物和放射进行的增殖性疾病的治疗
EP1951243B1 (en) Treatment of solid tumor diseases with combinations comprising imatinib and an efflux pump inhibitor
HK1075208B (en) Combinations comprising epothilones and pharmaceutical uses thereof
US20030139430A1 (en) Use of organic compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100622